Value of innovation for hematologic malignancies

Marchetti, Monia

doi:10.3111/13696998.2015.1133429

Cited by 5 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1st, the results have no universal value because they depend on the time horizon adopted and country-specific drug costs. 43 2nd, our analyses used a 3 rd -party payer perspective but did not consider indirect costs from productivity loss, a relevant social burden for young persons with MM. 44 3rd, unit costs of treatments resembled ex-factory costs and not true acquisition costs.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons With Multiple Myeloma.

Marchetti

Gale

Barosi

2021

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Considerable data indicate posttransplant lenalidomide prolongs progression-free survival and probably survival after an autotransplant for plasma cell myeloma (PCM). However, optimal therapy duration is unknown, controversial and differs in the EU and US. We compared outcomes and cost-effectiveness of 3 posttransplant lenalidomide strategies in EU and US settings: (1) none; (2) until failure; and (3) 2-year fixed duration. We used a Markov decision model which included 6 health states and informed by published data. The model estimated the strategy of lenalidomide given to failure achieved 1.06 quality-adjusted life years (QALYs) at costs per QALY gained of €29,232 in the EU and $133,401 in the US settings. Two-year fixed-duration lenalidomide averted €7,286 per QALY gained in the EU setting and saved 0.84 QALYs at $60,835 per QALY gained in the US setting. These extremely divergent costs per QALY in the EU and US settings resulted from large differences in costs of posttransplant lenalidomide and of 2nd-line therapies driven by whether posttransplant failure was on- or off-lenalidomide. In Monte Carlo simulation analyses which allowed us to account for variability of inputs, 2-year fixed-duration lenalidomide remained the preferred strategy for improving health-care sustainability in the EU and US settings.

show abstract

Section: Discussionmentioning

confidence: 99%